LGMN and Alzheimer disease: Considering that the oral plasma elimination half-life (t1/2) of δ-secretase inhibitor 11 in mice is too short, about 2.31 h, although this AEP inhibitor is effective in treating animals, its practical significance in the application to human AD is very limited.